Introduction
For more than a century, the cerebellar cortex has been an important model for studies concerning cortical histogenesis (Ramó n y Cajal, 1890). Neuronal migration is a basic cellular event essential for the precise integration of neurons in their correct destination place in the vertebrate brain (Sidman and Rakic, 1973; Rakic, 1988 Rakic, , 1990 .
During the development of the cerebellum, progenitor cells leave the rhombic lip and migrate tangentially to the neural tube over the surface of the cerebellar anlagen (Miale and Sidman, 1961 ) (for review, see Wingate, 2001) . These progenitor cells undergo several divisions and accumulate under the pia of the developing cerebellum to form the external granular layer (EGL) (Wingate and Hatten, 1999) . Once formed, subsequent divisions within the EGL give rise to postmitotic granule cells, which then migrate radially into the cerebellar cortex to form the internal granular layer (IGL) (Hatten, 1990; Rakic, 1990 ) (for review, see Hatten and Heintz, 1995) . The radial migration of granule cells toward the IGL is guided by a specialized form of radial glial cell, the so-called Bergman glia (Sidman and Rakic, 1973; Hatten, 1993 Hatten, , 1999 . During the glial-guided neuronal migration, a specialized migration junction, an interstitial junction, is present beneath the cell soma at the site of apposition with the glial fiber (Gregory et al., 1988) , and this close apposition suggests that membrane components of the cell surface mediate this migration.
Several molecules have been proposed to be involved in glialguided neuronal migration in the developing mammalian CNS (for review, see Pearlman et al., 1998; Hatten, 1999) . Recently, a cell surface glycolipid, the ganglioside 9-O-acetyl GD3, has been implicated in gliophilic neuronal migration. In antibody perturbation assays, it was demonstrated that the immunoblockage of this specific ganglioside with the monoclonal antibody Jones (mAb Jones) (Constantine-Paton et al., 1986) arrests neuronal migration in cerebellar slices and reduces the rate of neuronal migration by ϳ66% in cerebellar micro explants , suggesting that 9-O-acetyl GD3 is necessary for neuronal migration in cerebellar cultures.
In the present work, we tested in vivo whether the ganglioside 9-O-acetyl GD3 has a role in neuronal migration in the rat developing cerebellum. Early postnatal rats received sequential intraventricular injections of mAb Jones, and the proliferating neuroblasts in the EGL were labeled with intraperitoneal injections of 5-bromo-2Ј-deoxyuridine (BrdU). This method allowed us to evaluate the directional movement of granule cell precursors in the developing cerebellum and the putative role of the ganglioside 9-O-acetyl GD3 in this phenomenon.
Materials and Methods
Animals. Lister rats were obtained from our breeding colony. All experiments were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals, and the experimental protocols were approved by the Committee for the Use of Experimental Animals of our Institution.
Intraventricular injections. Postnatal day 7 (P7) rats were briefly anesthetized by ether inhalation and injected, with the assistance of a microsyringe, with 20 l of mAb Jones (IgM; Sigma, St. Louis, MO), mAb A2B5 (IgM; Boehringer Mannheim, Mannheim, Germany), or a sterile 0.9% saline. The needle was introduced in the posterior portion of the right lateral ventricle. Each animal was injected for 3 consecutive days at a 12 hr interval (a total of five injections) with mAb Jones (n ϭ 6), mAb A2B5 (n ϭ 4), or saline solution (n ϭ 3). The mAb Jones specifically recognizes the ganglioside 9-O-acetyl GD3 , and mAb A2B5 recognizes a group of the c-series gangliosides (Eisenbarth et al., 1979) and was used as a control Ig in our experiments.
Bromodeoxyuridine labeling and detection. Newly generated neurons were labeled with BrdU (Sigma), which is incorporated by cells synthesizing DNA (Gratzner, 1982) . Thirty minutes before each intraventricular injection, the animals received a dose of BrdU (100 mg/kg, i.p., dissolved in 0.007% NaOH in saline) and were killed 12 hr after the last intraventricular injection. Control animals from the same offspring were also injected with the drug (n ϭ 5). All of the experimental groups were processed for immunohistochemistry as described below. Briefly, the animals were perfused through the ascending aorta with 4% paraformaldehyde in 0.1 M phosphate buffer at pH 7.4. The cerebellum was then removed, cryoprotected by immersion in 20% phosphate-buffered sucrose, sectioned at 14 m, and collected onto gelatin-coated slides. After antigen retrieval in a microwave oven (Dover and Patel, 1994) , sections were washed with PBS and incubated overnight at 4°C with a mouse monoclonal antibody (IgG) against BrdU (Amersham Biosciences, Sao Paulo, Brazil), according to the instructions of the manufacturer, and developed with a Cy3-conjugated goat anti-mouse ␥-chain specific IgG (1:500; Jackson ImmunoResearch, West Grove, PA). Some sections were also labeled with a polyclonal antibody against GFAP (1:400; Dako, Renteria, CA) and goat anti-rabbit secondary antibody conjugated to Alexa 488 (1:200; Molecular Probes, Eugene, OR). The sections were then labeled with the fluorescent dye 4Ј-6-diamidino-2-phenylindole (DAPI) (Sigma, S. Louis, MO) or TO-PRO-3 (1:100; Molecular Probes) to visualize the nuclei and mounted in VectaShield (Vector Laboratories, Burlingame, CA). The stained cells were viewed and photographed under a Zeiss (Oberkochen, Germany) Axivert microscope equipped with a Zeiss AxioCam digital color camera connected to the Zeiss AxioVision 3.0 system. The extent of cell migration and the layer-specific localization of BrdU-labeled cells in the cerebellar cortex were analyzed.
In vivo immunohistochemistry. To analyze the diffusion and binding of the injected antibodies (mAb Jones and mAb A2B5), thick cryosections (40 m; as described above) were incubated for 2 hr at room temperature with a Cy3-conjugated -chain-specific goat anti-mouse (1:1000; Jackson ImmunoResearch). The sections were then counterstained with DAPI (Sigma) or TO-PRO-3 (Molecular Probes) and mounted in VectaShield. Three-dimensional projection reconstructed images (20 -40 m) were obtained using an LSM 510 Meta Zeiss confocal microscope. In initial experiments, to determine the availability of the antibodies in the brains, the animals received a single intraventricular injection of the antibody (Jones or A2B5) and were allowed to survive for 4, 8, 12, 16, or 24 hr after the injection. Animals were fixed, and cryosections were then obtained and analyzed for positive staining as described above. After the 4, 8, or 12 hr survival times, the staining was very strong in the cerebellum, whereas the 16 hr time was weak and absent 24 hr after the injection. Therefore, the interval of 12 hr was chosen for the intraventricular injections.
Quantitative analysis. Identical cerebellar regions (folia) with reference to the dorsoventral, anteroposterior, and mediolateral axes were used to compare the number of BrdU-labeled cells in the different animals. Three-dimensional projection reconstructed images (14 m) were obtained using an LSM 510 Meta Zeiss confocal microscope and analyzed using the Zeiss AxioVision 3.0 system. BrdU-stained cells were counted in the presumptive molecular layer (ML), Purkinje cell layer (PCL), and IGL of injected and control rats. In each experimental group, four adjacent cryostat sections were counted. The data from different experimental conditions were acquired using the morphometric tools of the Zeiss AxioVision 3.0 system. Statistical analysis was performed by ANOVA and the Tukey's multiple comparison post hoc test.
Results
The pattern of diffusion and staining of intraventricularly injected antibodies against gangliosides was evaluated incubating whole-brain cryosections of the injected animals with Cy3-conjugated secondary antibodies. In animals injected with the antibody against 9-O-acetyl GD3 4 -12 hr before fixation, we found immunolabeled cells restricted to very few regions of the brain. These regions include the subventricular zone, the rostral migratory stream in the forebrain, and the cerebellum. The staining pattern of mAb Jones in the cerebellum of a P9 animal is illustrated in Figure 1 A. Both the EGL and the presumptive ML display an intense staining in these animals. We also observe in this figure cells leaving the EGL with migratory profiles and expressing the 9-O-acetyl GD3 ganglioside in the cell bodies and also in the trailing and leading processes. In addition, a few cells in the IGL were also stained with mAb Jones. This pattern of staining of 9-O-acetyl GD3 using an in vivo immunohistochemistry was very similar to the expression pattern of 9-O-acetyl GD3 reported previously using immunogold histochemistry and electron microscope immunohistochemistry techniques.
In animals injected with the A2B5 antibody, the staining pattern was more diffuse than that described in the animals injected with Jones, and A2B5-positive cells were observed in all cerebellar layers (Fig. 1 B) . Some of the A2B5-labeled cells also display a migratory profile. No staining was found in the cerebellum or in any other brain region in saline-injected and control animals.
The intraventricularly injected and control animals received several intraperitonial injections of BrdU to label the cells in proliferation and to allow us to follow the postmitotic cell migration and to analyze the layer-specific localization of the BrdU-labeled cells in the cerebellar cortex. In control animals, several BrdUlabeled cells were found in the EGL, in the presumptive ML, PCL, and IGL (inner cerebellar layers) (Fig. 2 B) . A similar pattern of BrdU staining was observed in the cerebella of animals injected intraventricularly with saline (data not shown). In animals injected with mAb A2B5, we observe that the presence of the antibody for 3 d into the brain environment did not cause any significant effect on the extent of postmitotic granule cell migration. In these animals, BrdU-stained cells migrated through all cerebellar layers in a pattern very similar to that described in the cerebellum of control animals and saline-injected ones (data not shown). In contrast, injections of mAb Jones caused a drastic effect on the migration pattern of granule cells in equivalent folium of the developing cerebellum (Fig. 2C) . In these animals, the majority of postmitotic BrdU-labeled cells were arrested in the EGL, and only a small number of BrdU-positive cells reached the inner cerebellar layers (Fig. 2C) . The quantitative analysis of these data are represented in Figure 3 . The presence of mAb Jones in the cerebellum decreases by 43% the number of postmitotic BrdUpositive cells in the inner cerebellar layers when compared with the control groups (Fig. 3) .
We tested whether the injected antibody is interfering with the radial glia that gives support to the granule cell migration. The pattern of staining with GFAP in control (Fig. 4 A) and in mAb Jones-injected animals (Fig. 4) shows similar radial glia profiles, which suggest that the antibody does not affect the morphology of the these cells.
Discussion
Our results show that the intraventricular injection of mAb Jones in early postnatal animals labels cells in migratory regions of the developing brain, including the cerebellum. In these regions, cells are found with migratory profiles. The observation that labeling with Jones mAb is restricted to regions of cell migration is consistent with previous reports that have suggested that the ganglioside 9-O-acetyl GD3 is a marker for neuronal migration in the developing Schlosshauer et al., 1988; Mendez-Otero and Ramon-Cueto, 1994; Miyakoshi et al., 2001; Santiago et al., 2001 ) (for review, see Mendez-Otero and Santiago, 2001 ) and adult (Mendez-Otero and Cavalcante, 1996) nervous system. We also show that the antibody against 9-Oacetyl GD3 arrests granule cells in the external granular cell layer and diminishes the number of BrdU-positive granule cells in the internal granular cell layer by 57%. This effect is not attributable to an interference with the glial radial fibers that support cell migration in this system with the exit of the cells from the cell cycle, because shorter treatments with the antibody do not affect cell migration and proliferation .
Recently, it has been proposed that gangliosides and other glycolipids are present in specialized membrane microdomains named "glycosynapses" (Hakomori, 2002) . It has also been suggested that these molecular assemblies can mediate cell adhesion and/or signal transduction events through tetraspanin-integringanglioside complexes (Zheng et al., 1993; Mannion et al., 1996; Hemler, 1998; Ono et al., 2000 Ono et al., , 2001 Wang et al., 2001 ). In addition, it has been shown that ␣3␤1 integrin plays a key role in the control of glial-guided neuronal migration during the formation of the cerebral cortex layers (Dulabon et al., 2000) , and ␤1 integrin expression has been described in the cerebellum during development (Husmann and Sievers, 1985) . These results combined with results described in this paper and previous reports from our group (for review, see Mendez-Otero and Santiago, 2001 ) support the assumption that 9-O-acetyl GD3 may interact with integrin receptors and therefore be involved in the control and/or modulation of the neuron-glia interactions and, consenquently, in the neuronal migration program during cerebellar development. Because gangliosides have been associated with glycosynapses in non-neuronal cells, it would be interesting to verify whether such structures are also present in the developing cerebellum and their role in the gliophilic migration of granule cells. 
